POST Online Media Lite Edition


Capstone Therapeutics appoints Robert J. Spiegel to board of directors

Staff writer |
Tempe, Ariz., USA - May 25, 2010, Tempe, Ariz., USA - Capstone Therapeutics Corp., a biotechnology company, announced the appointment of Robert J. Spiegel to its board of directors.

Dr. Spiegel has more than 25 years of executive-level pharmaceutical development and product commercialization experience with Schering-Plough. Until his retirement in November 2009, Dr. Spiegel held the position of Chief Medical Officer at Schering-Plough and was a member of their Pharmaceutical Leadership Board and Corporate Licensing Review Board; he was also Chairman of Schering-Plough's Safety Review Board and Preparedness Response Committee (Crisis Control).

While with Schering-Plough, Dr. Spiegel was involved in the filing of over thirty NDA submissions and interacted with US FDA and EU regulatory authorities on a regular basis, serving on the executive committees overseeing all research projects and drug licensing activities. He also served as the lead Schering-Plough representative in numerous joint venture development projects with biotechnology and other large pharmaceutical partnerships.

Dr. Spiegel originally joined Schering-Plough as Director, Clinical Research, progressing through clinical operations as Vice President, Clinical Research, Senior Vice President, Worldwide Clinical Research, becoming Chief Medical Officer in 1998.


What to read next

Delek Logistics expands its board
PTC Therapeutics names Tuyen Ong as chief medical officer
Capstone Mining appoints director